Last Updated: 18/03/2025
Evaluation of the IgG antibody response against different allelic forms of the Plasmodium vivax circumsporozoite protein in sera from individuals from malaria endemic areas
Objectives
*Original title in Portuguese: Avaliação da resposta de anticorpos IgG contra diferentes formas alélicas da proteína circunsporozoíta de Plasmodium vivax em soros de indivíduos de áreas endêmicas de malária
This project proposes to express and purify recombinant proteins corresponding to allelic variants of the P. vivax circumsporozoite protein (VK210, VK247 and P. vivax-like) in Escherichia coli bacteria to evaluate the prevalence and magnitude of IgG antibodies against the different variants of PvCSP in human serology.
Malaria is an acute febrile infectious disease associated with high morbidity, especially in countries located in the tropical zone of the planet. According to the Pan American Organization, the African region, especially, concentrates around 90% of all malaria cases and deaths worldwide and fifteen countries, of which 14 are located in Sub-Saharan Africa, carry 80% of the global burden of malaria. In Brazil, the majority of cases of the disease are concentrated in the Amazon region, which accounts for 99% of cases registered in the country. The Plasmodium parasite has a complex biological cycle and is becoming increasingly resistant to medications, making it necessary to develop a safe and effective vaccine, as it is a relevant strategy for preventing and controlling malaria. Therefore, vaccine formulations containing more than one antigen from different stages of P. vivax have been explored, and previous studies by our group have described the importance of proteins such as MSP119 and CSP as immunodominant antigens.
May 2024 — Nov 2024
Related Resources
